What is CAROS?
The origins of this organization date back to the spring of 1989, when a multidisciplinary steering committee was formed to outline the essential qualities of a national research plan for schizophrenia. It was agreed at that time that the plan should build on existing research strengths in Canada and make the best use of our unique Canadian resources. The first of these is our population: many Canadian families exhibit a relatively stable pattern of geographical distribution over several generations, ideal for genetic studies using a pedigree strategy. Also considered was our health care system, which allows good record keeping and follow-up of patients with schizophrenia impossible in many other countries. The steering committee recommended holding a workshop to bring together a diversified group of researchers, mental health Can. J. Psychiatry Vol. 35, November 1990 655 professionals, administrators and representatives of schizophrenia advocacy groups drawn from all regions of Canada. The workshop was held in the fall of 1989 and the paticipants endorsed many of the recommendations of the steering committee. Although no consensus was reached on priorities for research on schizophrenia in Canada, the workshop participants suggested the formation of an interim committee to address these priorities and to begin to formulate an administrative structure for a more permanent organization. The interim committee met subsequently on two occasions, in April and July of 1990, and as a result the Canadian Alliance for Research on Schizophrenia was formed. The organization consists of two main arms: an administrative arm that will be involved with advocacy concerning funding related to schizophrenia research, and a research arm that would consist of six research panels. The panels will focus on the following subjects: 1. genetics; 2. psychopharmacology; 3. neurobiology and imaging; 4. psychosocial factors and treatments; 5. consumer and family issues; and 6. health care delivery systems. A seventh panel will examine instrumentation issues in order to standardize the use of rating scales and diagnostic interview schedules, a crucial issue for all subsequent work dealing with the national plan.
Why CAROS?
The most important reason for the development of CARaS is to improve research on schizophrenia in Canada, both in terms of the funding available and the quality of research that is derived from that funding base. Inadequacies in funding for schizophrenia research have arisen for many reasons. These include a low priority in the public mind due to the stigma of mental illness, a lack of strong advocacy groups, and a paucity of quality research programs designed to study the disorder. Recently however, there has been improvement in these areas. Advocacy for patients with schizophrenia has improved due to the formation of the Canadian Friends of Schizophrenics (soon to be renamed the Schizophrenia Society of Canada) and the development of consumer advocacy groups. In addition, the stigma and ignorance surrounding the disease is gradually being replaced with empathy and understanding as information from media coverage of the disease spreads. There have also been a number of important scientific developments that suggest the possibility of significant breakthroughs in schizophrenia research, a number of which have occurred in Canada. Although unsuccessful in obtaining funding, a recent proposal to the Network of Centres of Excellence competition dealing CANADIAN JOURNAL OF PSYCHIATRY Vol. 35, No.8 specifically with schizophrenia research was well received by the scientific community, suggesting that there are a sufficient number of investigators now in Canada. The time would therefore seem ripe to advocate increased funding for this disease and to develop a national plan for research that takes full advantage of that funding.
Who is CAROS?
CARas was formed as a result of the recommendations of the workshop participants -neuroscientists, geneticists, epidemiologists, psychopharmacologists, social scientists, service providers, consumers and advocates from across Canada. As a result membership in CARaS attempts to reflect that broad representational base. The organization will include members from groups such as the Canadian Mental Health Association, Canadian Friends of Schizophrenics, consumer groups and service providers. Research input into CARaS will be provided by the six research panels. The chairs of each panel will represent their areas of specialty in CARaS and thus determine the objectives of the organization, including the development of a national research plan. The nature of the research panels should provide a broad multidisciplinary representation that balances biological and psychosocial aspects of the disease.
Where is CAROS?
In practical terms the organization, having arisen from advocacy efforts on the part of Canadian 'Friends of Schizophrenics, will be best housed within this organization.
This would be consistent with the objectives of Canadian Friends of Schizophrenics to increase research funding and to support research activities for this disease. The broad representation within CARaS will hopefully prevent duplication of these activities. Conceptually, CARaS is nationally based. In its advocacy role, focus would not only be placed on the federal government but on provincial and private funding sources. In its role as research coordinator, its principal objectives would be to standardize instrumentation used in research into schizophrenia and to create a national network of centres which, depending on the specific research orientation, would share common protocols and maintain unitary data banks.
When will CAROS Propose a National Plan?
CARaS is committed to developing a national plan for research into schizophrenia in Canada within the next year. Research panels have been giv.en the task of developing inventories of researchers and available technologies within their given areas of expertise. They have been asked to put forward proposals for research programs in their own areas and suggestions for proposals that will involve other areas. After these reports have been compiled, the main body of CARaS will meet to prioritize and submit recommendations to the federal government. It is hoped that a national plan for schizophrenia research will be financially supported not only through the normal peer review funding agencies but also in the form of special allocation of funds to develop this plan and support schizophrenia research in this country.
In the subsequent article An Update of the Epidemiology of Schizophrenia by Drs. Beiser and Iacono, some of the methodological problems that have arisen in schizophrenia research are addressed. Many of those problems can only be solved through national strategies which will allow for large sample sizes, the collection of data on rare cases such as drug naive subjects, and the development of common assessment procedures. Also a national research effort is necessary to make possible long term investigations carried out within an interactive and multidisciplinary framework. It is hoped that a national plan for schizophrenia research in Canada will meet these needs and that the Canadian Alliance for Research on Schizophrenia can successfully arrive at a consensus of what that national plan shall be.
